Invention Grant
- Patent Title: Treatment of fibrodysplasia ossificans progressiva
-
Application No.: US16579126Application Date: 2019-09-23
-
Publication No.: US11407822B2Publication Date: 2022-08-09
- Inventor: Sarah J. Hatsell , Aris N. Economides , Vincent J. Idone
- Applicant: REGENERON PHARMACEUTICALS, INC.
- Applicant Address: US NY Tarrytown
- Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee Address: US NY Tarrytown
- Agency: Alston & Bird LLP
- Agent Christopher Westberg
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/22 ; C07K16/18 ; A61K38/17 ; C07K16/28 ; C07K14/705 ; A61K39/00
Abstract:
Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVR1) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVR1 and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVR1 or Activin A.
Information query
